Conference Home

Scientific Agenda

Accommodations & Travel


Call for Abstracts

12th Canadian Melanoma Conference: Research Frontiers

OncologyEducation is proud present the 12th Canadian Melanoma Conference. The Canadian Melanoma Conference is Canada’s international flagship meeting on the research and treatment of melanoma. This event will take place February 22nd-25th, 2018 at the Fairmont Banff Springs Hotel in Banff, Alberta, Canada.

Target Audience

This conference brings together medical oncologists, surgeons, dermatologists, radiotherapists, pathologists, molecular biologists, immunologists, and other allied health professionals interested in the treatment of melanoma worldwide. 

About the Program Chair

Dr. Scott Ernst, Head, Division of Medical Oncology, London Regional Cancer Program

Program Planning Committee:

Dr. Michael Smylie, Medical Oncologist, Cross Cancer Institute; Professor, Division of Medical Oncology, University of Alberta

Dr. Teresa Petrella, Medical Oncologist, Sunnybrook Odette Cancer Centre; Associate Professor, University of Toronto

Dr. Joel Claveau, Dermatologist, Melanoma and Pigmented Lesions Clini Hôpital Hôtel Dieu de Québec

Dr. David Hogg, Professor of Medicine, Departments of Medicine and Medical Biophysics, University of Toronto

Dr. J. Gregory McKinnon, Professor of Surgery and Oncology, University of Calgary and Tom Baker Cancer Centre

Dr. Thomas G. Salopek, Associate Professor and Divisional Director, Division of Dermatology and Cutaneous

Science, University of Alberta

Dr. Alan Spatz, Professor of Pathology and Oncology, McGill University; Canada Research Chair in Molecular

Pathology; Director, Department of Pathology, Jewish General Hospital

Dr. Carman Giacomantonio, Nova Scotia Health, Associate Professor / Surgical Oncologist, Dalhousie University

Other Information

Please direct any questions to Andrea Segal, Senior Event Manager, at

Oncology Clinical News

Celgene Settles Whistle-Blower Fraud Suit for $280 Million

(Bloomberg) July 25, 2017 - Celgene Corp. agreed to pay $280 million to resolve a whistle-blower’s claims the drugmaker used illegal marketing tactics to turn its Thalomid and Revlimid cancer drugs into blockbuster sellers, the U.S. said.
Read full article.

Eisai Submits Simultaneous Applications In The United States And Europe For Lenvatinib In Hepatocellular Carcinoma

(Eisai) July 25, 2017 - Eisai Co., Ltd. announced that it has submitted applications to the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its in-house discovered and developed anticancer agent lenvatinib mesylate (lenvatinib) for the treatment of hepatocellular carcinoma (HCC).
Read full article.

Roche Gains CE Label Expansion For Companion Diagnostic To Identify ALK-positive Non-small Cell Lung Cancer Patients

(Yahoo! Finance) July 25, 2017 - Roche today announced that it has obtained a CE mark for the VENTANA anti-ALK (D5F3) Rabbit Monoclonal Primary Antibody as a companion diagnostic to identify ALK-positive non-small cell lung cancer (NSCLC) patients eligible for treatment with the Novartis drug ZYKADIA (ceritinib).
Read full article.

Powered by OBR Oncology